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Introduction
In septic shock, the vasoconstriction in splanchnic vessels is
disproportionally greater than in other vascular beds and may
persist despite the presence of normal systemic hemo-
dynamic measurements [1]. Takala and Ruokonen found, in
spite of normal global cardiopulmonary physiology, that
1H-MRS = proton magnetic resonance spectroscopy; MEGX = monoethylglycinexylidide; MR = proton magnetic resonance; NAC = N-acetylcys-
teine; PaO2/FiO2 = partial arterial oxygen tension/inspirator oxygen fraction.
Abstract
Background N-acetylcysteine (NAC) has been shown to improve splanchnic blood flow in experimental
studies. This report evaluates the effects of NAC on liver perfusion and lactate signal intensities in the
liver tissue of septic shock patients using proton magnetic resonance imaging and spectroscopy.
Furthermore, the monoethylglycinexylidide (MEGX) test was used to investigate hepatic function.
Methods Five septic shock patients received 150 mg/kg body weight NAC as an intravenous bolus
injection over 15 min. Lidocaine was injected both prior to and following NAC administration in order to
determine MEGX formation. Measurements (hemodynamics, oxygen transport-related variables, blood
samples for lactate, liver-related markers) were performed 1 hour before and 1 hour after NAC
injection. In addition to the proton magnetic resonance imaging patients received two proton magnetic
resonance spectra, one prior to and one 30 min subsequent to the onset of the NAC infusion at a
1.5 Tesla clinical scanner, for measurement of liver perfusion and liver lactate signal intensity.
Main findings Following NAC infusion, the lactate signal intensity in the liver tissue showed a median
decrease of 89% (11–99%), there was a median increase in liver perfusion of 41% (–14 to 559%), and
the MEGX serum concentration increased three times (1.52–5.91).
Conclusions A decrease in the lactate signal intensity in the liver tissue and an increase in the MEGX
serum concentration and in liver perfusion might indicate improved liver function as a result of NAC
administration. Patients with compromised hepatosplanchnic function, such as patients with septic
shock due to peritonitis, may therefore benefit from NAC therapy.
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inadequate perfusion and oxygenation of the splanchnic
region increases the risk of Multiple Organ Dysfunction
Syndrome [2]. The gut is described as the ‘motor’ of Multiple
Organ Dysfunction Syndrome [3].
N-acetylcysteine (NAC), a precursor of glutathione synthesis,
can exert important antioxidant cytoprotective effects and
anti-inflammatory effects [4–8]. When endotoxic shock
occurred, there was a significant increase in the absolute
mesenteric blood flow but not in the fractional blood flow (i.e.
hepatic flow index/cardiac index) following NAC administra-
tion [4,9]. In patients, NAC has been shown to increase the
cardiac index and oxygen delivery in fulminant hepatic failure
and in septic shock [4,6,10]. Devlin and colleagues showed
in a recent study that the indocyanine green elimination in
patients with hepatic dysfunction increased after NAC admin-
istration [11]. It is not clear, however, whether the increase in
elimination rate is related to an increased hepatosplanchnic
perfusion or to a better hepatic function [12].
The aim of this report was therefore to investigate whether
the administration of NAC improves liver function and liver
blood flow in septic shock patients. Owing to the fact that
splanchnic dysoxia is usually presumed in sepsis [13], we
focused on the measurement of lactate in the liver tissue
accumulating following cell dysfunction [14]. Furthermore,
the monoethylglycinexylidide (MEGX) test was used to inves-
tigate hepatic function.
Materials and methods
All patients were included after written informed consent of
legislative and ethical committee approval. For continuous
cardiovascular monitoring a fiber optic, pulmonary artery flota-
tion catheter (Baxter Swan-Ganz® Intelicath™ continuous
cardiac output thermodilution catheter 139H — 7.5 French;
Baxter/Edwards Critical-Care, Irvine, California, USA) and a
radial artery catheter were inserted. After adequate fluid
resuscitation, norepinephrine was titrated to maintain the
mean arterial pressure between 70 and 90 mmHg. All
patients were mechanically ventilated and received a continu-
ous infusion of the analgesic sedatives fentanyl and fluni-
trazepam. The mechanical ventilation was pressure controlled
(Servo 900 C; Siemens, Solna, Sweden), and ventilator set-
tings were not altered during the study period. All patients
were normoventilated (arterial carbon dioxide tension =
35–45 Torr). None of the patients had a change in body tem-
perature > 0.5°C during the study period, as documented by
continuous monitoring of a catheter thermistor.
Blood was collected and hemodynamic measurements were
performed 1 hour before and 1 hour after NAC injection.
Patients received 150 mg/kg body weight NAC as an intra-
venous bolus injection over 15 min. Each hemodynamic mea-
surement included the heart rate and cardiovascular
pressures with reference to the midaxillary line. The hemo-
dynamic measurements were immediately followed by the
withdrawal of mixed venous and radial artery blood samples.
Part of each sample was immediately analyzed for arterial and
mixed venous oxygen and carbon dioxide tensions (ABL 300;
Radiometer, Copenhagen, Denmark), along with arterial and
mixed venous hemoglobin content and oxygen saturation
(Hemoximeter OSM-3; Radiometer).
An intravenous bolus of 1 mg/kg body weight lidocaine was
injected 1 hour before and 1 hour after NAC administration.
Blood samples to determine the MEGX test were taken
before and 15 min after lidocaine injection. The serum con-
centration of the lidocaine metabolite MEGX was determined
by means of a fluorescence polarization immunoassay
(Abbott GmbH, Wiesbaden, Germany). MEGX concentration
values measured before lidocaine administration were sub-
tracted from concentrations measured after 15 min, and the
results were reported as serum MEGX concentrations
(ng/ml). Blood samples were centrifuged at 4650 × g for
10 min, and serum was stored at –80°C until analysis.
The measurements of bilirubin, aspartate aminotransferase,
alanine aminotransferase and serum lactate were analyzed as
part of the clinical routine (Clinical Chemistry Department).
Proton magnetic resonance spectroscopy (1H-MRS) mea-
surements for measurement of lactate liver intensities were
acquired at a 1.5 Tesla clinical scanner (Magnetom Vision;
Siemens) with a stimulated echo acquisition mode sequence.
A fast imaging procedure was performed prior to spec-
troscopy using a technique involving a gradient echo
sequence, fast low angle shot (FLASH 2D), while the breath
was held for several seconds. In these images a volume of
interest of 64 ml resolution was positioned in the liver
parenchyma of the right lobe. A localized shimming proce-
dure was performed. The number of acquisitions was 256.
We used echo times of 135 ms and 270 ms, respectively, to
differentiate between the fatty acid signal and the lactate
signal at 1.35 ppm. This was necessary as both signals
consist of almost identical resonance frequencies but have
different phase angles at varied echo times. Evaluation of the
spectra was performed by means of the LC Model program
[15] and data are expressed in arbitrary units that correspond
to micromoles per liter. The liver perfusion measurement was
performed with the gadolinium-enhanced proton magnetic
resonance (MR) imaging method [16,17].
Results
Five septic shock patients were evaluated. Septic shock was
defined according to the criteria for septic shock of the
American College of Chest Physicians Consensus Confer-
ence [18]. All patients were studied within the first 24 hours
of the onset of sepsis. Acute Physiology and Chronic Health
Evaluation II [19] and Multiple Organ Dysfunction [20] scores
were recorded. Basic patient characteristics, scores,
outcome data, laboratory parameters and hemodynamic-
related and ventilator-related data for each patient areR68
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presented in Table 1. The results for liver perfusion, liver
lactate signal intensity and MEGX serum concentrations are
shown in Figs 1–3, respectively.
Discussion
The most important results of this report were threefold.
There was a median decrease of 89% in lactate signal inten-
sities in liver tissues, although the plasma lactate did not
change markedly. Second, there was an increase in liver per-
fusion after NAC application and, finally, there was an
improvement in liver function measured by the MEGX plasma
concentration.
Liver function test and MEGX formation
All patients had MEGX concentrations lower than 50 ng/ml
prior to administration of NAC (i.e. hepatic dysfunction was
manifest) [21,22], without remarkable elevation in conven-
tional routine parameters such as aspartate aminotransferase,
alanine aminotransferase, bilirubin or serum lactate. After the
treatment with NAC the 15 min MEGX concentration showed
an increase up to 4.6-fold. The rate of hepatic uptake of lido-
caine and MEGX elimination depends primarily on the hepatic
blood flow, while MEGX is formed by P-450 in hepatic micro-
somes [4,22–24]. Cytochrome P-450 is predominantly local-
ized in zone 3 of the hepatic lobule. In a nonseptical setting,
MEGX formation increased due to an improved blood flow
[23,25]. NAC may enhance zone 3 perfusion by increasing
sinusoidal blood flow, since zone 3 misdistribution may exist
in septic shock patients [21,22,26].
Liver lactate and MR spectroscopy
All patients showed a decrease in the lactate signal intensi-
ties in their liver tissue. In an animal study, Salzman and col-
leagues showed a significant transmesenteric lactate
Table 1
Patient data: basic patient characteristics, scores, hemodynamic-related parameters, and laboratory parameters
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Sex Male Male Female Male Male
Age (years) 66 74 84 61 47
Sepsis source Pneumonia Pneumonia/urosepsis Peritonitis Peritonitis Peritonitis
Survivor Yes Yes No Yes Yes
N-acetylcysteine Pre Post Pre Post Pre Post Pre Post Pre Post
APACHE II (points) 27 24 26 23 24 22 26 21 22 20
MOD score (points) 9 11 11 9 11 11 9 9 7 5
HR (beats/min) 121 122 100 102 116 118 119 100 62 76
MAP (mmHg) 98 90 86 83 88 74 71 83 80 74
CI (l/min/m2) 3.4 3.8 3.7 4.3 3.0 3.8 4.2 4.5 7.0 6.1
NE (µg/kg/min) 0.09 0.14 0.47 0.47 0.64 1.27 0.48 0.48 0.05 0.00
PaO2/FiO2 (Torr) 307 217 260 151 314 266 172 179 218 236
Lactate (mmol/l) 1.0 1.7 1.6 1.6 3.5 2.5 1.9 1.2 1.3 0.9
ALAT (U/l) 16 38 17 39 15 14 5 5 16 8
ASAT (U/l) 19 48 20 49 22 18 6 8 12 9
Bilirubin (µmol/l) 40 44 15 13 58 83 20 17 54 38
ALAT, alanine aminotransferase; APACHE II, Acute Physiologic and Chronic Health Evaluation; ASAT, aspartate aminotransferase; CI, cardiac
index; HR, heart rate; MAP, mean arterial pressure; MOD, Multiple Organ Dysfunction; NE, norepinephrine; PaO2/FiO2, partial arterial oxygen
tension/inspirator oxygen fraction.
Figure 1
Liver perfusion: liver signal intensity before (pre) and after (post)
















concentration (lactate between arterial and mesenteric
venous blood) increase after a 90 min ileal hypoxic period
[27]. An in vitro study has shown that cell dysfunction leads
to the inhibition of pyruvate dehydrogenase within minutes,
thus leading to a pyruvate and lactate accumulation in the cell
[14]. Accordingly, the decrease in liver lactate signal intensi-
ties identified in the present report could be due to a
decreased splanchnic lactate production as a result of a
NAC-induced increase in regional perfusion with improve-
ment in microcirculation. The improvement in liver perfusion in
four patients could be directly associated with the decrease
in liver lactate signal intensities. This assumption is supported
by the fact that MEGX formation increased after NAC appli-
cation as a sign of an improved hepatic oxidative metabolism.
The beneficial effects of NAC on tissue perfusion have
already been shown in animal and clinical studies [10,26].
Blood lactate levels did not change. In order to cause a sig-
nificant increase in blood, the rate of lactate production must
exceed skeletal muscle, renal and hepatic uptake [28]. Since
we did not measure hepatic lactate uptake or release to
plasma it is difficult to say what should be expected.
We chose 1H-MRS to determine biochemical changes in
hepatic tissue. To the best of our knowledge, no studies have
been published concerning 1H-MRS determination of lactate
signal intensities in liver tissue in vivo. Only one previous
paper exists, which describes in vivo 1H-MRS of the liver,
assigning the peaks of carnitin, taurine, glutamate and gluta-
min [29]. Studies have been carried out on human bile and
cerebral samples and on animals referring to lactate signal
intensities in liver tissue [30–32]. 1H-MRS is often used to
determine lactate in other tissues (e.g. cerebral tissue) [33].
The technical advantage of 1H-MRS is its increased sensitiv-
ity; with an equal quantity of nuclei, it is approximately
15 times more sensitive than 31P-MR spectroscopy.
Furthermore, the effects of respiratory motions complicate
liver studies. We decided against respiration synchronization,
as this would have required three times as much measuring
time. We used the stimulated echo acquisition mode in con-
junction with water suppression techniques [34]. Spectral
evaluation and quantification of metabolite concentrations
was based on a fully automated program [31]. The spectra,
however, have to be regarded critically. The resonance
sequences can only be identified with an optimal signal/noise
ratio. Therefore, the quantity of acquisitions is important.
Acquisitions, similar to respiration synchronization, lead to a
time problem. At a later stage, the signal/noise ratio depends
on the coil. We used the body coil; however, a local surface
coil would have optimized the signal/noise ratio.
Liver blood flow and MR imaging
In order to measure the liver perfusion, we selected gadolin-
ium-enhanced MR imaging as a noninvasive assessment
[16,17]. To the best of our knowledge, liver blood flow mea-
surements have not been performed to date in humans, but
portal venous flow, azygos venous blood flow and focal liver
lesion blood flow measurements have been carried out in pre-
vious studies [35–37]. Our measurements were taken in the
manual expiration hold at the respirator. Otherwise noise,
which can worsen the signal/noise ratio, and the respiratory
motions would lead to an inconsistent slice position and
reproduction. The MR imaging in our study showed a median
improvement of 41% in liver perfusion in our patients associ-
ated with a decrease in lactate signal intensities in liver
tissue, and an increase in four patients in the cardiac index.
The increase in cardiac index after NAC administration has
already been shown in clinical studies [6,10]. These results
suggest that NAC may have a beneficial effect on regional
perfusion, which has already been shown in clinical and
Available online http://ccforum.com/content/8/2/R66
Figure 2
Liver lactate signal intensity before (pre) and after (post)


















Monoethylglycinexylidide (MEGX) measurements before (pre) and after
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experimental studies [4,9]. The decrease in pulmonary vascu-
lar and systemic vascular resistance has been illustrated in
some studies on endotoxemia in animals [9,38].
The vasodilating effects of NAC may be caused by a direct
relaxing action on vascular smooth muscle or by modulation of
nitric oxide, which activates guanylate cyclase, leading to an
increase in cyclic guanosine monophosphate accumulation
and smooth muscle relaxation [4,39]. This vasodilating property
could have been the cause of the decrease in the PaO2/FiO2
ratio seen in three of the five patients and of the increase in the
norepinephrine dose seen in two of the five patients after NAC
application, with a consecutive improvement in the PaO2/FiO2
ratio several hours after the intervention.
Conclusions
This report has shown, for the first time, that NAC decreases
liver lactate signal intensities and increases perfusion mea-
sured by MR imaging and spectroscopy. The MEGX forma-
tion improved in all patients, probably due to a NAC-induced




1. Edouard AR, Degremont AC, Duranteau J: Hetereogenous
regional vascular responses to simulated transient hypo-
volemia in men. Intensive Care Med 1994, 20:414-420.
2. Takala J, Ruokonen E: Regional blood flow and oxygen trans-
port in septic shock. Crit Care Med 1993, 21:1296-1303.
3. Deitch E: The role of intestinal barrier failure and bacterial
translocation in the development of systemic infection and
multiple organ failure. Arch Surg 1990, 125:403-408.
4. Rank N, Michel C, Haertel C, Lenhart A, Welte M, Meier-Hellmann
A, Spies C: N-acetylcysteine increases liver blood flow and
improves liver function in septic shock patients: results of a
prospective, randomized, double-blind study. Crit Care Med
2000, 28:3799-3807.
5. Aruoma OI, Halliwell B, Hoey BM, Butler B: The antioxidant
action of N-acetylcysteine; its reaction with hydrogen perox-
ide, hydroxyl radical, superoxide, and hypochlorous acid.
J Free Radic Biol Med 1989, 6:593-597.
6. Harrison PM, Wendon JA, Gimson AES, Graeme JMA, Williams
R:  Improvement by acetylcysteine of haemodynamics and
oxygen transport in fulminant hepatic failure. N Engl J Med
1991, 324:1852-1857.
7. Fox ES, Brower JS, Bellezo JM, Leingang KA: N-acetylcysteine
and α α-tocopherol reverse the inflammatory response in acti-
vated rat Kupffer cells. J Immunol 1997, 158:5418-5423.
8. Miller EJ, Cohen AB, Matthay MA: Increased interleukin-8 con-
centrations in the pulmonary edema fluid of patients with
acute respiratory distress syndrom from sepsis. Crit Care Med
1996, 24:1448-1454.
9. Zhang H, Spapen H, Nguyen DN, Rogiers P, Bakker J, Vincent JL:
Effects of N-acetyl-L-cysteine on regional blood flow during
endotoxic shock. Eur Surg Res 1995, 27:292-300.
10. Spies C, Reinhart K, Witt I, Meier-Hellmann A, Hannemann L,
Donald L, Bredle PD, Schaffartzik W: Influence of N-acetylcys-
teine on indirect indicators of tissue oxygenation in septic
shock patients: results from a prospective, randomized,
double-blind study. Crit Care Med 1994, 22:1738-1746.
11. Devlin J, Ellis AE, McPeake J, Heaton N, Wendon JA, Williams R:
N-acetylcysteine improves indocyanine green extraction and
oxygen transport during hepatic dysfunction. Crit Care Med
1997, 26:236-242.
12. Ott P: Effects of N-acetylcysteine on hepatic blood flow and
function [letter]. Crit Care Med 1998, 26:415.
13. De Backer D, Creteur J, Noordally O, Small N, Bulbis B, Vincent
JL:  Does hepato-splanchnic VO2/DO2 dependency exist in
critically ill septic patients? Am J Respir Crit Care Med 1998,
157:1219-1225.
14. Kilpatrick-Smith L, Erecinska M: Cellular effects of endotoxin in
vitro: I. Effect of endotoxin on mitochondrial substrate metab-
olism and intracellular calcium. Circ Shock 1983, 11:85-99.
15. Provencher SW: Estimation of metabolite concentrations from
localized in vivo NMR. Magn Reson Med 1993, 30:672-679.
16. Brix G, Schreiber W, Hoffmann U, Guckel F, Hawighorst H,
Knopp MV: Methodological approaches to quantitative evalua-
tion of microcirculation in tissues with dynamic magnetic res-
onance tomography. Radiologe 1997, 37:470-480.
17. Zapletal C, Mehrabi A, Scharf J, Hess T, Kraus T, Herfarth C, Klar
E:  Experimental evaluation of dynamic MRI for quantifying
liver perfusion. Langenbecks Arch Chir 1998, Suppl I:581-584.
18. American College of Chest Physicans/Society of Critical Care
Medicine Consensus Conference: Definitions for sepsis and
organ failure and guidelines for the use of innovative thera-
pies in sepsis. Crit Care Med 1992, 20:864-874.
19. Knaus WA, Wagner DP, Draper EA, Zimmermann JE: APACHE II:
a severity disease classification. Crit Care Med 1992, 13:818-
828.
20. Goris RJA, Boekhorst TPA, Nuytnick JKS: Multiple organ failure.
Arch Surg 1985, 120:1109-1115.
21. Igonin AA, Armstrong VW, Shipkova M, Kukes VG, Oellerich M:
The monoethylglycinexylidine (MEGX) test as a marker of
hepatic dysfunction in septic patients with pneumonia. Clin
Chem Lab Med 2000, 38:1125-1128.
22. Oellerich M, Raude E, Burdelski M, Schulz M, Schmidt FW, Ringe
B, Lamesch P, Pichlmayr P, Raith H, Scheruhn M, Wrenger M,
Wittekind CH: Monoethylglycinxylidide formation kinetics. A
novel approach to assessment of liver function. J Chem Clin
Biochem 1987, 25:845-853.
23. Goldfarb B, Debaene B, Ang ET, Roulot D, Jolis P, Lebrec D:
Hepatic blood flow in humans during isoflurane-N2O and
halothane-N2O anesthesia. Anesth Analg 1990, 71:349-353.
24. Imakoa S, Enomoto K, Oda Y, Asada A, Fujimori M, Shimada T,
Fujita H, Guenderich FP, Funae Y: Lidocaine metabolism by
human cytochrome P-450s purified from hepatic micro-
somes: comparison of those with rat hepatic cytochrome
P-450s. J Pharmacol Exp Ther 1990, 255:1385-1391.
25. Oda Y, Kariya N, Nakamoto T, Nishi S, Asada A, Fujimori M: The
monoethylglycinexylidide test is more useful for evaluating
liver function than indocyanine green test: case of a patient
with remarkably decreased indocyanine green half-life. Ther
Drug Monit 1995, 17:207-210.
26. Koeppel TA, Thies JC, Lehmann T, Gebhar MM:. Improvement of
hepatic microhemodynamics by N-acetylcysteine after warm
ischemia. Eur Surg Res 1996, 28:270-277.
27. Salzman AL, Wang H, Wollert PS, Vandermeer JT, Compton CC,
Denenberg AG, Fink MP: Endotoxin-induced ileal mucosal
hyperpermeability in pigs: role of tissue acidosis. Am J Physiol
1994, 266:G633-G646.
28. Kruse JA, Carlson RW: Lactate metabolism. Crit Care Clin
1987, 3:725-746.
29. Bárány M, Langer BG, Glieck RP, Venkatasubramanian NP,
Wilbur AC, Spigos DG: In vivo 1-H spectroscopy in humans at
1.5 T. Radiology 1988, 167:839-844.
30. Nishijima T, Nishina M, Fujiwara K: Measurement of lactate
levels in serum and bile using proton magnetic resonance in
patients with hepatobiliary disease: its utility in detection of
malignancies. Jpn J Clin Oncol 1997, 27:13-17.
Key messages
• N-acetylcysteine decreases liver lactate signal 
intensities in magnetic resonance spectroscopy
• N-acetylcysteine increases liver perfusion measured by
magnetic resonance imaging
• N-acetylcysteine improves MEGX formationR71
31. Lockett CJ, Busza AL, Proctor TA, Churchill TA, Williams SR,
Fuller BJ: Proton nuclear magnetic resonance spectroscopy of
lactate production in isolated rat liver during cold preserva-
tion. Cryobiology 1996; 33:271-275.
32. Chung Y, Jue T: 1H NMR observation of redox potential in liver.
Biochemistry 1992, 31:11159-11165.
33. Frahm J, Hanefeld F: Localized proton magnetic resonance
spectroscopy of cerebral metabolites. Neuropediatrics 1996,
27:64-69.
34. Frahm J, Merboldt KD, Hanicke W: Localised proton spec-
troscopy using stimulated echos. J Magn Reson 1987, 72:502-
508.
35. Kuo PC, King L, Alfrey JE, Jeffry RB, Garcia G, Dafoe CD: Mag-
netic resonance imaging and hepatic haemodynamics: corre-
lation with metabolic function in liver transplantation
candidates. Surgery 1995, 117:373-379.
36. Lomas DJ, Hayball MP, Jones DP, Sims C, Allison ME, Alexander
GJ: Non-invasive measurements of azygos venous blood flow
using magnetic resonance. J Hepatol 1995, 22:399-403.
37. Taupitz M, Speidel A, Hamm B, Deimling M, Reichel M, Bock A,
Wolf KJ: T2-weighted breath-hold MR-imaging of the liver at
1.5 T: results with a three-dimensional steady-state free pro-
cession sequence in 87 patients. Radiology 1995,  194:439-
446.
38. Bernard GR, Lucht WD, Niedermeyer ME, Snapper JR, Ogletree
ML, Brigham KL: Effect of N-acetylcysteine on the pulmonary
response to endotoxin in the awake sheep and upon in vitro
granulocyte function. J Clin Invest 1984, 73:1772-1784.
39. Waldmann SA, Murad F: Biochemical mechanisms underlying
vascular smoth muscle relaxation: the guanylate cyclase-
cyclic GMP system. J Cardiovasc Pharmakol 1988, 12:115-118.
Available online http://ccforum.com/content/8/2/R66